Use of long-acting insulin analogues in type 2 diabetes mellitus treatment (according to the data of international and Russian registries)


Cite item

Full Text

Abstract

The article is concerned with issues of insulin therapy in patients with type 2 diabetes mellitus (DM2). Indications for early insulin therapy in these patients are presented. Algorithm for treatment of DM2 considers insulin as a antihyperglycemic drug with greatest efficiency. The data for the possible use in DM2 of insulin glargine (Lantus) - a long-acting insulin analogue providing the need for a basal insulin for 24 hours - are presented. It is shown that one injection of insulin glargine in addition to the everyday treatment of DM2 in patients treated with oral antihyperglycemic drugs, who not achieve target values of blood glucose - a simple and effective way to rapid and lasting results. The use of insulin glargine is accompanied by improved glycemic control, lower levels of glycated hemoglobin, reduced risk of nocturnal hypoglycemia, and increased patient's complacency.

About the authors

M B Antsiferov

M Antsiferov

References

  1. Wild S, Roglic G, Green A, et al. Global prevalence of diabetes: estimates for the year 2000 and projections for 2030. Diabetes Care 2004;27:1047-53.
  2. Шестакова М.В., Дедов И.И. "Сахарный диабет и хроническая болезнь почек", М. 2009, 17 с.
  3. Rodbard H, Jellinger P, Davidson J. et al. Statement by an American Association of Clinical Endocrinologists/American College of Endocrinology consensus panel on type 2 diabetes mellitus: an algorithm for glycemic control. Endocrine practice: official journal of the American College of Endocrinology and the American Association of Clinical Endocrinologists 2009;15(6):540-59.
  4. Simon D, et al. Mortality in a representative sample of diabetic patients in France - the ENTRED Study. EASD 44 Annual Meeting, 2008; Abstract 416.
  5. Nathan DM, Buse JB, Davidson MB, et al. Medical management of hyperglycemia in type 2 diabetes: a consensus algorithm for the initiation and adjustment of therapy: a consensus statement of the American Diabetes Association and the European Association for the Study of Diabetes. Diabetes Care 2009;32(1):193-203.
  6. American Diabetes Association. Clinical Practice Recommendations. Implications of the United Kingdom Prospective Diabetes Study. Diabetes Care 2003;26(1):28-32.
  7. Nathan DM, Buse JB, Davidson MB, et al. Management of hyperglycemia in type 2 diabetes: A consensus algorithm for the initiation and adjustment of therapy: a consensus statement from the American Diabetes Association and the European Association for the Study of Diabetes. Diabetes Care 2008,31:1-11.
  8. Ramlo-Halsted BA, Edelman SV. The natural history of type 2 diabetes. Implications for clinical practice. Primary Care 1999;26:771-789,
  9. De Fronzo RA. Insulin resistance: multifaceted syndrome responsible for NIDDM, obesity, hypertension, dyslipidemia and atherosclerosis. Neth J Med 1997;50:191-197.
  10. Сунцов Ю.И., Дедов И.И., Шестакова М.В. "Скрининг осложнений сахарного диабета как метод оценки качества лечебной помощи больным". М. 2008. 58 с.
  11. UKPDS Group. Diabetes 1995;44:1259-58.
  12. Wright A, Burden AC, Paisey RB, et al. Sulfonylurea inadequacy: efficacy of addition of insulin over 6 years in patients with type 2 diabetes in the U.K. Prospective Diabetes Study (UKPDS 57). Diabetes Care 2002;25:330-6.
  13. Riddle M, Rosenstock J, Gerich J, et al. The treat-to-target trial: randomized addition of glargine or human NPH insulin to oral therapy of type 2 diabetic patients. Diabetes Care 2003;26:3080-6
  14. Gerstein HC, Yale JF, Harris SB, et al. A randomized trial of adding insulin glargine vs. avoidance of insulin in people with Type 2 diabetes on either no oral glucose-lowering agents or submaximal doses of metformin and/or sulphonylureas. The Canadian INSIGHT (Implementing New Strategies with Insulin Glargine for Hyperglycaemia Treatment) Study. Diabetes Med 2006;23:736 42.
  15. Bretzel RG, Nuber U, Landgraf W, et al. Once-daily basal insulin glargine versus thrice-daily prandial insulin lispro in people with type 2 diabetes on oral hypoglycaemic agents (APOLLO): an open randomised controlled trial. Lancet 2008;371:1073-84.
  16. Yki-Jаrvinen H, Juurinen L, Alvarsson M, et al. Initiate Insulin by Aggressive Titration and Education (INITIATE): a randomized study to compare initiation of insulin combination therapy in type 2 diabetic patients individually and in groups. Diabetes Care 2007;30:1364-9.
  17. Riddle M, Rosenstock J, Gerich J et al. The treat-to-target trial: randomized addition of glargine or human NPH insulin to oral therapy of type 2 diabetic patients. Diabetes Care 2003;26:3080-6
  18. Анциферов М.Б., Петранева Е.В. Возможности применения инсулина гларгина (Лантус) для лечения сахарного диабета типа 2 в работе амбулаторной эндокринологической службы: результаты анализа регистра LAURЕL // Фарматека. 2009. № 3. С. 65-69.
  19. Leahy JL, et al. Diabetologia 2008;51(1):405.
  20. Sharplin P, Gordon J, Peters JR, et al. Improved glycaemic control by switching from insulin NPH to insulin glargine: a retrospective observational study. Cardiovasc Diabetol 2009;19(8):3.
  21. Schreiber SA, Haak T, et al. Insulin glargine benefits patients with type 2 diabetes inadequately controlled on oral antidiabetic treatment: an observational study of everyday practice in 12,216 patients. Diabetes Obes Metab 2007;9(1):31-38;
  22. Schreiber SA, Haak T, Ferlinz K, et al. The long-term efficacy of insulin glargine plus oral antidiabetic agents in a 32-month observational study of everyday clinical practice. Diabetes Technol Ther 2008;10(2):121-127
  23. Eliaschewitz FG, Calvo C, Valbuena H, et al. Therapy of type 2 diabetes: insulin glargin vs. NPH insulin both in combination with glimepiride. Arch Med Res 2006;37:495-501.
  24. Ray КК, Seshasai SD, Wijesuriya S, et al. Effect of intensive control of glucose on cardiovascular outcomes and death in patients with diabetes mellitus: a meta-analysis of randomised controlled trials. Lancet 2009;373:1765-72.
  25. http://www.pharmateca.ru/cgi-bin/statyi.pl?sid=2519&mid=1085056570&magid=187

Supplementary files

Supplementary Files
Action
1. JATS XML
Download

Copyright (c) 2010 Bionika Media

This website uses cookies

You consent to our cookies if you continue to use our website.

About Cookies